Karina Sultankulova: Smarter D-Dimer Strategies for Safe and Efficient DVT Exclusion
Karina Sultankulova, Clinical Director at American Medical Centers, shared on LinkedIn about a recent article by Menno V Huisman and Kenneth A Bauer, published in UpToDate, adding:
”In clinical practice, ruling out Deep Vein Thrombosis (DVT) using a fixed D-dimer cutoff of 500 ng/mL often leads to over-testing, especially in older adults where baseline levels naturally rise.
Modern, evidence-based strategies allow us to safely optimize efficiency without compromising patient safety:
1. Age-adjusted cutoff
For patients >50 years old with a low/moderate pretest probability, use the following validated formula:
Age (years) x 10 ng/mL
The evidence:
Data from a multicenter prospective study of 3,205 patients showed that this approach safely ruled out DVT without compression ultrasonography (CUS).
At 3 months, there were zero VTE events in patients who fell between the fixed 500 ng/mL and their higher age-adjusted limit.
The impact: In patients ≥75 yo, it tripled the number of people who could safely avoid unnecessary imaging (16% vs. 5% using the conventional cutoff), significantly increasing specificity.
2. Pretest probability (PTP)-Adjusted Cutoff
This strategy adjusts the D-dimer threshold based on clinical risk assessment (e.g., Wells Score):
Low PTP: DVT is excluded if D-dimer is <1000 ng/mL.
Moderate PTP: DVT is excluded if D-dimer is <500 ng/mL.
The Impact: Clinical studies show this reduces the overall need for ultrasound scans by 8% to 47%, maintaining an incredibly safe missed-thrombosis rate of less than 0.6% during follow-up.
Key takeaway:
Adopting adjusted D-dimer cutoffs reduces unnecessary diagnostic imaging, lowers healthcare costs, and spares elderly patients from redundant hospital stress – all while safely excluding thromboembolic events.”
Title: Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity
Authors: Menno V Huisman, Kenneth A Bauer

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin